利妥昔单抗联合环磷酰胺后序贯贝利尤单抗治疗狼疮性肾炎的II期随机试验
这项多中心、随机、开放标签II期试验纳入43例复发或难治性狼疮性肾炎患者,比较利妥昔单抗+环磷酰胺+糖皮质激素后每周贝利尤单抗输注至第48周(RCB组)与不加贝利尤单抗(RC组)的安全性和初步疗效。结果显示加用贝利尤单抗未增加不良事件,但第48周完全或部分肾脏缓解率两组差异无统计学意义(52% vs 41%,P=0.452),贝利尤单抗组B细胞计数更低并抑制过渡型向初始B细胞成熟。
要点
- 加用贝利尤单抗未增加难治性狼疮性肾炎患者的不良事件发生率。
- 第48周肾脏缓解率贝利尤单抗组52%对对照组41%,差异无统计学意义。
- 贝利尤单抗降低B细胞数量并减少初始B细胞比例,增强自身反应性B细胞清除。
核心结论
- 在利妥昔单抗和环磷酰胺方案基础上加用贝利尤单抗对难治性狼疮性肾炎患者是安全的,但与传统B细胞清除策略相比未改善临床疗效。
- 贝利尤单抗在B细胞重建过程中削弱过渡型向初始B细胞的成熟,并增强自身反应性B细胞的阴性选择。
研究设计与样本
- 多中心、随机、开放标签II期临床试验,纳入43例复发或难治性狼疮性肾炎患者,随访至第96周。
- 患者随机接受利妥昔单抗+环磷酰胺+糖皮质激素后每周贝利尤单抗输注至第48周(RCB组,21例)或不加贝利尤单抗(RC组,22例)。
- 采用流式细胞术分析外周血总B细胞和自身反应性B细胞亚群百分比。
主要发现
- 第48周完全或部分肾脏缓解在RCB组为11/21(52%),RC组为9/22(41%),P=0.452。
- 治疗失败的主要原因是狼疮性肾炎无改善或恶化。
- 两组均出现B细胞清除,贝利尤单抗组B细胞百分比更低(第60周B细胞几何均数53 cells/μl vs 11 cells/μl,P=0.0012)。
- 两组总过渡型B细胞和自身反应性过渡型B细胞百分比从基线至第48周均增加。
- 贝利尤单抗组总初始B细胞和自身反应性初始B细胞百分比从基线至第48周下降,与无贝利尤单抗组比较P=0.0349。
关键数值与推荐
- 第48周完全或部分肾脏缓解率:RCB组52%(11/21)vs RC组41%(9/22),P=0.452。
- 第60周B细胞几何均数:RCB组53 cells/μl vs RC组11 cells/μl,P=0.0012。
- 初始B细胞百分比变化组间比较P=0.0349。
临床怎么用
- 对难治性狼疮性肾炎,利妥昔单抗联合环磷酰胺后加用贝利尤单抗安全性可接受,但本试验未显示临床疗效获益。
- 贝利尤单抗可降低B细胞数量并抑制过渡型向初始B细胞成熟,可作为理解B细胞靶向序贯治疗机制的参考。
局限性
- 样本量小(共43例),为开放标签设计,初步疗效结论需更大规模试验验证。
- 随访至第96周,但主要疗效分析在第48周,长期肾脏结局数据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the safety, mechanism of action, and preliminary efficacy of rituximab followed by belimumab in the treatment of refractory lupus nephritis (LN). METHODS: In a multicenter, randomized, open-label clinical trial, 43 patients with recurrent or refractory LN were treated with rituximab, cyclophosphamide (CYC), and glucocorticoids followed by weekly belimumab infusions until week 48 (RCB group), or treated with rituximab and CYC but no belimumab infusions (RC group). Patients were followed up until week 96. Percentages of total and autoreactive B cell subsets in the patients' peripheral blood were analyzed by flow cytometry. RESULTS: Treatment with belimumab did not increase the incidence of adverse events in patients with refractory LN. At week 48, a complete or partial renal response occurred in 11 (52%) of 21 patients receiving belimumab, compared to 9 (41%) of 22 patients in the RC group who did not receive belimumab (P = 0.452). Lack of improvement in or worsening of LN was the major reason for treatment failure. B cell depletion occurred in both groups, but the percentage of B cells remained lower in those receiving belimumab (geometric mean number of B cells at week 60, 53 cells/μl in the RCB group versus 11 cells/μl in the RC group; P = 0.0012). Percentages of total and autoreactive transitional B cells increased from baseline to week 48 in both groups. However, percentages of total and autoreactive naive B cells decreased from baseline to week 48 in the belimumab group compared to the no belimumab RC group (P = 0.0349), a finding that is consistent with the observed impaired maturation of naive B cells and enhanced censoring of autoreactive B cells. CONCLUSION: The addition of belimumab to a treatment regimen with rituximab and CYC was safe in patients with refractory LN. This regimen diminished maturation of transitional to naive B cells during B cell reconstitution, and enhanced the negative selection of autoreactive B cells. Clinical efficacy was not improved with rituximab and CYC in combination with belimumab when compared to a therapeutic strategy of B cell depletion alone in patients with LN.
引用
- Atisha-Fregoso Y, Malkiel S, Harris KM, et al. Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis. Arthritis Rheumatol. 2020. PMID: 32755035. doi:10.1002/art.41466
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。